Cilomilast-d9(Synonyms: 西洛司特 d9)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Cilomilast-d9 (Synonyms: 西洛司特 d9)

Cilomilast-d9 (SB-207499-d9) 是 Cilomilast 的氘代物。Cilomilast (SB-207499) 是一种有效的，选择性的和具有口服活性的磷酸二酯酶 4 (PDE4) 抑制剂，对 LPDE4 和 HPDE4 的 IC50 值分别约为 100 和 120 nM。 Cilomilast 对 PDE4 的选择性高于 PDE1，PDE2，PDE3 和 PDE5 (IC50=74，65，>100，83 µM)。Cilomilast 具有抗炎和免疫调节作用，可用于哮喘和慢性阻塞性肺疾病 (COPD) 的研究。

Cilomilast-d9(Synonyms: 西洛司特 d9)

Cilomilast-d9 Chemical Structure

CAS No. : 1794779-92-2

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Cilomilast-d9 (SB-207499-d9) is the deuterium labeled Cilomilast. Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 µM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD)[1][2][3][4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

352.47

Formula

C20H16D9NO4
CAS 号

1794779-92-2
中文名称

西洛司特 d9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Griswold DE, et, al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.

    [3]. Hatzelmann A, et, al. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79.

    [4]. Barnette MS, et, al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther. 1998 Jan;284(1):420-6.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务